Assembly Actions - Lowercase Senate Actions - UPPERCASE |
|
---|---|
Mar 11, 2020 | reported referred to ways and means |
Jan 28, 2020 | referred to health |
Archive: Last Bill Status - In Assembly Committee
- Introduced
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed/Vetoed by Governor
Your Voice
Actions
Co-Sponsors
Dan Quart
Diana Richardson
Robert C. Carroll
David Weprin
A9634 (ACTIVE) - Details
A9634 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 9634 I N A S S E M B L Y January 28, 2020 ___________ Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN, SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on Health AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (gg) to read as follows: (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES- SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER. SUCH MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI- ZATION MANDATE. § 2. Subdivision 26-b of section 364-j of the social services law, as added by section 4 of part B of chapter 69 of the laws of 2016, is amended to read as follows: 26-b. Managed care providers shall not require prior authorization for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formu- lary form of the drug or as otherwise required by section 1927(k)(6) of the Social Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER. § 3. Subdivision 10 of section 273 of the public health law, as added by section 5 of part B of chapter 69 of the laws of 2016, is amended to read as follows: 10. Prior authorization shall not be required for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets